Fig. 6From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisForest plot of progression free survival. Subgroup analysis for progression free survival. PFS, progression free survival; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoproteinBack to article page